Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Has Stake In Three Of Nine NCATS Research Projects

This article was originally published in The Pink Sheet Daily

Executive Summary

Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.

Advertisement

Related Content

Pfizer CTI Research Network Expands With NIH Collaboration
NIH Drug Repurposing Program Produces Surprise Overlaps
NCATS Opens Repurposing Project With 58 Compounds, 17 From Pfizer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel